3 withdrawn. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Withdrawn 3 |
| Phase 1 | 2 | Withdrawn 2 |
Follow Papulopustular Rosacea: new trials by email Literature Review of Papulopustular Rosacea trials Research Report on Papulopustular Rosacea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Deucravacitinib Rosacea Deucravacitinib, Placebo - Papulopustular Rosacea | Phase 2 | Withdrawn | Icahn School of Medicine at Mount Sinai | 2024-11-01 | 2025-01-24 | |
| Study to Evaluate the Safety of ATR-04 ATR-04, Placebo - Epidermal Growth Factor, Papulopustular Rosacea | Phase 1 / Phase 2 | Withdrawn | Azitra Inc. | 2024-01-01 | 2025-10-03 | |
| A Safety and Efficacy Study to Evaluate Rosacea AIV001, Vehicle - Papulopustular Rosacea | Phase 1 / Phase 2 | Withdrawn | AiViva BioPharma, Inc. | 2021-07-01 | 2024-12-17 |
Rosacea (3)
Skin Diseases (3) · Skin and Connective Tissue Diseases (3)
deucravacitinib (1)
AiViva BioPharma, Inc. (1) · Azitra Inc. (1) · Icahn School of Medicine at Mount Sinai (1)
United States (2)
Benjamin Ungar (1) · Mitchell Goldman, MD (1)